Om

Scribe Therapeutics Inc. is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. Its platform uses custom-engineered enzymes and delivery technologies to create precise therapies designed to address the root causes of disease. The company’s current work centers on cardiometabolic conditions, including cardiovascular and metabolic diseases, with programs aimed at key drivers of atherosclerotic cardiovascular disease. Scribe Therapeutics also advances epigenetic silencing approaches intended to deliver durable therapeutic effects without permanently altering DNA. Based in Alameda, California, Scribe Therapeutics operates at the intersection of gene editing, molecular engineering, and drug development, serving the growing field of genetic medicine with technologies designed for broad clinical use in common diseases.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I SCRIBE THERAPEUTICS MED ENDAVU: Køb Scribe Therapeutics ($SCTX) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Scribe Therapeutics, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.